Drugs / 99mTc-1-thio-D-glucose
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04288518 | Feb 2020 → Feb 2021 | neoplasm | Tomsk National Research Medical Center of the Russian Academy of Sciences | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT07475390 | Feb 2026 → Dec 2027 expected | brain glioma | Tomsk National Research Medical Center of the Russian Academy of Sciences | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 99mTc-1-thio-D-glucose | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07475390 ↗ |
| Known as | technetium-99m labeled 1-Thio-D-Glucose | “SPECT Imaging of Brain Tumors Using Technetium-99m Labeled 1-Thio-D-Glucose (99mTc-1-thio-D-glucose).” NCT04288518 ↗ |
| Modality | Diagnostic / imaging agent | “after a single injection in a diagnostic dosage” NCT04288518 ↗ |
| Route | Intravenous | “after a single intravenous administration” NCT04288518 ↗ |